{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65736d39d32e730012c98919/65d8d615dc02e000160b676f?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Prime Editing for Isogenic iPSCs, PRINT, Universal In Vivo CAR T Editing, Biogen Q4 Results Disappoint; Andrea Choe","description":"<p><strong>Episode 10 (February 23, 2024): </strong>Researchers from Francis Collins’ lab developed an efficient CRISPR prime editing protocol to generate isogenic-induced pluripotent stem cell (iPSC) lines carrying heterozygous or homozygous alleles for putatively causal single nucleotide variants. An RNA-based system known as PRINT can create and introduce site-specific, safe, and stable transgenes into the human genome. Astellas Pharma and Kelonia announced a nearly $800 million research collaboration and license agreement to develop innovative universal, off-the-shelf in vivo CAR T cell therapies. Fourth-quarter earnings and revenue fell short of expectations as Biogen worked to eliminate 1,000 jobs (11.5% of its workforce), among other cost-cutting actions, and restructured its pipeline after a slow start.</p><p>&nbsp;</p><p>Plus, an interview with Andrea Choe, founder and chief executive officer at Holoclara.</p><p>&nbsp;</p><p>Listed below are key references to the <em>GEN</em> stories, media, and other items discussed in this episode of <em>Touching Base</em>:</p><p>&nbsp;</p><p><a href=\"https://www.liebertpub.com/doi/10.1089/crispr.2023.0066\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Generation of Human Isogenic Induced Pluripotent Stem Cell Lines with CRISPR Prime Editing</strong></a></p><p><em>The CRISPR Journal</em>, February 14, 2024</p><p>&nbsp;</p><p><a href=\"https://www.liebertpub.com/doi/10.1089/genbio.2024.29132.ebi\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Addressing Scientific Misconduct: An Interview with Elisabeth Bik</strong></a></p><p>By Uduak Thomas, <em>GEN Biotechnology</em>, February 15, 2024</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/drug-discovery/stockwatch-biogens-q4-results-disappoint-analysts/\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>StockWatch: Biogen’s Q4 Results Disappoint Analysts</strong></a></p><p>By Alex Philippidis, <em>GEN Edge</em>, February 18, 2024</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/genome-editing/astellas-and-kelonia-partner-for-800m-in-vivo-car-t-cell-therapies/\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Astellas and Kelonia Partner for $800M In Vivo CAR T Cell Therapies</strong></a></p><p>By Jonathan D. Grinstein, PhD, <em>GEN Edge</em>, February 20, 2024</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/genome-editing/print-precise-rna-mediated-insertion-of-transgenes/\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>PRINT: Precise RNA-Mediated Insertion of Transgenes</strong></a></p><p><em>GEN</em>, February 21, 2024</p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}